Drug intelligence / Profile preview

ublituximab + umbralisib + bendamustine

Development stage: Unknown
Lead developer: TG Therapeutics
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

Ublituximab + umbralisib (TGR-1202) + bendamustine is a combination therapy under investigation for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL)[1][4][5]. Ublituximab is a glycoengineered monoclonal antibody targeting CD20 on B cells to induce immune-mediated lysis. Umbralisib (TGR-1202) is an orally available phosphoinositide 3-kinase delta inhibitor that blocks PI3Kδ signaling in malignant B cells. Bendamustine is an alkylating agent that crosslinks DNA and induces cell death[4][6]. The combination leverages non-overlapping mechanisms to enhance anti-tumor activity in patients with advanced or refractory NHL who may not be eligible for high-dose chemotherapy or stem cell transplant[1][4].

Other names: U2 regimenU-2 regimenU 2 regimenTGR-1202TGR1202TGR 1202

Targets

DNAPIK3CD (Phosphatidylinositol 3-kinase delta)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on ublituximab + umbralisib + bendamustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ublituximab + umbralisib + bendamustine.

Explore the full profile